Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report / Altavilla, A; Procopio, G; Alesini, D; Grillone, F; Massari, F; Zaniboni, A; Mattioli, R; Buti, S; Garanzini, E; Sisani, M; Hamzaj, A; Marrocolo, F; De Angelis, V; Bracarda, S. - In: I SUPPLEMENTI DI TUMORI. - ISSN 2283-5423. - 15:1(2014), pp. S128-S128.
Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report
Buti S;
2014-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
